查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2019566

全球聚乙二醇化市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global PEGylation Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 166 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計聚乙二醇化市場將從 2025 年的 27.2 億美元成長到 2034 年的 77.2 億美元，2026 年至 2034 年的複合年成長率為 12.3%。

全球聚乙二醇化（PEGylation）市場正經歷快速成長，其主要驅動力是藥物研發和生物技術領域應用的不斷拓展。聚乙二醇化是一種將聚乙二醇（PEG）鏈連接到分子上的技術，能夠提高藥物的穩定性、溶解度和體內停留時間。生物製藥和標靶治療需求的不斷成長是推動市場擴張的主要因素。此外，藥物研發的進步也加速了針對多種疾病的聚乙二醇化藥物的開發。

主要成長要素包括人們對提高藥物療效和減少副作用日益成長的興趣。聚乙二醇化技術廣泛應用於蛋白質藥物和療法的研發。生物製藥產業的擴張以及研發投入的增加也促進了市場成長。此外，隨著個人化醫療的日益普及，對先進藥物遞送技術的需求也不斷成長。

由於生物技術和製藥科學的持續創新，聚乙二醇化市場預計未來將顯著成長。下一代聚乙二醇化技術的開發將進一步提升藥物的性能。在新興市場，由於對醫療保健和生物技術投資的增加，預計將出現強勁的成長機會。此外，對新療法應用的持續研究也將繼續推動市場擴張。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球聚乙二醇化市場：依產品與服務分類

  • 市場分析、洞察與預測
  • 消耗品
  • 服務

第5章：全球聚乙二醇化市場：依蛋白質類型分類

  • 市場分析、洞察與預測
  • 集落刺激因子
  • 干擾素
  • 促紅血球生成素
  • 重組因子VII
  • 其他

第6章：全球聚乙二醇化市場：依應用領域分類

  • 市場分析、洞察與預測
  • 癌症
  • 自體免疫疾病
  • 肝炎
  • 多發性硬化症
  • 血友病
  • 消化系統疾病
  • 其他

第7章：全球聚乙二醇化市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 製藥和生物技術公司
  • 受託研究機構
  • 學術研究機構

第8章：全球聚乙二醇化市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Thermo Fisher Scientific Inc
    • Abcam Plc
    • Enzon Pharmaceuticals Inc
    • Merck KGaA
    • Celares GmbH
    • Profacgen
    • Creative PEGworks
    • NOF America Corp
    • Aurigene Pharmaceutical Services Ltd
    • Laysan Bio Inc
簡介目錄
Product Code: VMR11216591

The PEGylation Market size is expected to reach USD 7.72 Billion in 2034 from USD 2.72 Billion (2025) growing at a CAGR of 12.3% during 2026-2034.

The global PEGylation market is witnessing rapid growth due to its increasing application in drug development and biotechnology. PEGylation involves attaching polyethylene glycol (PEG) chains to molecules, enhancing drug stability, solubility, and circulation time in the body. The growing demand for biologics and targeted therapies is a key factor driving market expansion. Additionally, advancements in pharmaceutical research are supporting the development of PEGylated drugs for various medical conditions.

Key growth drivers include the rising focus on improving drug efficacy and reducing side effects. PEGylation technology is widely used in the development of protein-based drugs and therapeutics. The expansion of the biopharmaceutical industry and increasing investments in research and development are also contributing to market growth. Furthermore, the growing adoption of personalized medicine is boosting demand for advanced drug delivery technologies.

In the future, the PEGylation market is expected to grow significantly with continuous innovation in biotechnology and pharmaceutical sciences. The development of next-generation PEGylation techniques will further enhance drug performance. Emerging markets are likely to offer strong growth opportunities due to increasing investments in healthcare and biotechnology. Additionally, ongoing research into novel therapeutic applications will continue to drive market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product & Services

  • Consumables
  • Services

By Protein Type

  • Colony-stimulating Factor
  • Interferons
  • Erythropoietin
  • Recombinant Factor VII
  • Others

By Application

  • Cancer
  • Autoimmune Diseases
  • Hepatitis
  • Multiple Sclerosis
  • Hemophilia
  • Gastrointestinal Disorders
  • Others

By End-user

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academic & Research Institutes

COMPANIES PROFILED

  • Thermo Fisher Scientific Inc, Abcam plc, Enzon Pharmaceuticals Inc, Merck KGaA, Celares GmbH, Profacgen, Creative PEGworks, NOF America Corp, Aurigene Pharmaceutical Services Ltd, Laysan Bio Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PEGYLATION MARKET: BY PRODUCT & SERVICES 2022-2034 (USD MN and Tons)

  • 4.1. Market Analysis, Insights and Forecast Product & Services
  • 4.2. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 4.3. Services Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)

Chapter 5. GLOBAL PEGYLATION MARKET: BY PROTEIN TYPE 2022-2034 (USD MN and Tons)

  • 5.1. Market Analysis, Insights and Forecast Protein Type
  • 5.2. Colony-stimulating Factor Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 5.3. Interferons Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 5.4. Erythropoietin Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 5.5. Recombinant Factor VII Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)

Chapter 6. GLOBAL PEGYLATION MARKET: BY APPLICATION 2022-2034 (USD MN and Tons)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 6.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 6.4. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 6.5. Multiple Sclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 6.6. Hemophilia Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 6.7. Gastrointestinal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 6.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)

Chapter 7. GLOBAL PEGYLATION MARKET: BY END-USER 2022-2034 (USD MN and Tons)

  • 7.1. Market Analysis, Insights and Forecast End-user
  • 7.2. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 7.3. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
  • 7.4. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)

Chapter 8. GLOBAL PEGYLATION MARKET: BY REGION 2022-2034 (USD MN and Tons)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Tons)
    • 8.2.1 By Product & Services
    • 8.2.2 By Protein Type
    • 8.2.3 By Application
    • 8.2.4 By End-user
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Tons)
    • 8.3.1 By Product & Services
    • 8.3.2 By Protein Type
    • 8.3.3 By Application
    • 8.3.4 By End-user
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Tons)
    • 8.4.1 By Product & Services
    • 8.4.2 By Protein Type
    • 8.4.3 By Application
    • 8.4.4 By End-user
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Tons)
    • 8.5.1 By Product & Services
    • 8.5.2 By Protein Type
    • 8.5.3 By Application
    • 8.5.4 By End-user
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Tons)
    • 8.6.1 By Product & Services
    • 8.6.2 By Protein Type
    • 8.6.3 By Application
    • 8.6.4 By End-user
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PEGYLATION INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Thermo Fisher Scientific Inc
    • 10.2.2 Abcam Plc
    • 10.2.3 Enzon Pharmaceuticals Inc
    • 10.2.4 Merck KGaA
    • 10.2.5 Celares GmbH
    • 10.2.6 Profacgen
    • 10.2.7 Creative PEGworks
    • 10.2.8 NOF America Corp
    • 10.2.9 Aurigene Pharmaceutical Services Ltd
    • 10.2.10 Laysan Bio Inc